Serum B2-microglobulin and human immunodeficiency virus infection in intravenous drug users: a cross-sectional study. NLM AIDSLINE Important note: Information in this article was accurate in 1993. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


Serum B2-microglobulin and human immunodeficiency virus infection in intravenous drug users: a cross-sectional study.

Boll Ist Sieroter Milan. 1990 Jun;69(2):447-8. Unique Identifier : AIDSLINE MED/93090344
De Mercato R; Rezza G; Giuliani M; Perna E; Iovinella V; Bassi A; Tagliaferro R; Universita degli Studi di Napoli, II Facolt di Medicina.

Abstract: Beta 2-microglobulin level has been evaluated in 183 male intravenous drug users and 50 apparently healthy blood donors. The aim of the study was to assess the possible association between high values of the peptide and both HIV infection and disease progression in intravenous drug users. Beta 2-microglobulin values were found significantly higher in AIDS patients and other symptomatic subjects than in asymptomatic, both seropositive and seronegative, intravenous drug users. Among asymptomatic drug users, no significant difference in the values was found.
Keywords: beta 2-Microglobulin/*ANALYSIS Biological Markers Cross-Sectional Studies Human HIV Infections/BLOOD/*COMPLICATIONS/EPIDEMIOLOGY HIV Seroprevalence Italy/EPIDEMIOLOGY Male Predictive Value of Tests Sensitivity and Specificity Substance Abuse, Intravenous/BLOOD/*COMPLICATIONS/EPIDEMIOLOGY JOURNAL ARTICLEKWDbeta2-microglobulin/KWDanalysisbiologicalmarkerscross-sectionalstudieshumanhivinfections/blood/KWDcomplications/epidemiologyhivseroprevalenceitaly/epidemiologymalepredictivevalueoftestssensitivityandspecificitysubstanceabuse,intravenous/blood/KWDcomplications/epidemiologyjournalarticle
930330
M9331091

Copyright © 1993 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1993. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1993. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .